BioNexus Gene Lab (BGLC) Income towards Parent Company (2018 - 2025)
Historic Income towards Parent Company for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to -$708991.0.
- BioNexus Gene Lab's Income towards Parent Company rose 4730.14% to -$708991.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.3 million, marking a year-over-year decrease of 16676.32%. This contributed to the annual value of -$1.6 million for FY2024, which is 3846.25% up from last year.
- According to the latest figures from Q3 2025, BioNexus Gene Lab's Income towards Parent Company is -$708991.0, which was up 4730.14% from -$616172.0 recorded in Q2 2025.
- BioNexus Gene Lab's Income towards Parent Company's 5-year high stood at $671809.0 during Q4 2021, with a 5-year trough of -$2.6 million in Q3 2023.
- Moreover, its 5-year median value for Income towards Parent Company was -$63621.0 (2024), whereas its average is -$263310.9.
- Over the last 5 years, BioNexus Gene Lab's Income towards Parent Company had its largest YoY gain of 77148.37% in 2023, and its largest YoY loss of 327100.17% in 2023.
- BioNexus Gene Lab's Income towards Parent Company (Quarter) stood at $671809.0 in 2021, then tumbled by 107.79% to -$52349.0 in 2022, then surged by 771.48% to $351515.0 in 2023, then plummeted by 197.1% to -$341331.0 in 2024, then plummeted by 107.71% to -$708991.0 in 2025.
- Its Income towards Parent Company was -$708991.0 in Q3 2025, compared to -$616172.0 in Q2 2025 and -$623327.0 in Q1 2025.